FDA grants accelerated approval to GSK’s Jemperli for MSI‑H/dMMR locally advanced rectal cancer

The U.S. Food and Drug Administration approved Jemperli (dostarlimab‑gxly) under an accelerated pathway for adults with stage II‑III MSI‑H/dMMR locally advanced rectal cancer. The decision relied on the phase II AZUR‑1 trial, which showed that a substantial share of patients achieved a sustained clinical complete response at 12 months. GSK said the immunotherapy could let eligible patients avoid chemotherapy, radiation and surgery, offering a more personalized treatment option.

The approval adds a new indication to Jemperli, creating a potential revenue stream for GSK in a biomarker‑defined subset of rectal cancer patients (about 5‑10% of cases). The label expansion also benefits partner AnaptysBio, which co‑develops the drug, by increasing its commercial exposure.

  • 1The FDA granted accelerated approval on 19 Oct 2026 for adults with stage II‑III MSI‑H/dMMR locally advanced rectal cancer.
  • 2In the AZUR‑1 trial, 47 % of independent‑review‑evaluable patients reached a 12‑month clinical complete response (cCR12).
  • 3Investigator‑assessed data showed 68 % of evaluable patients achieved cCR12.
  • 4An exploratory analysis reported that 76 % of evaluable patients had no detectable cancer after at least one year of follow‑up.
  • 5Serious adverse reactions occurred in 20 % of patients; the most common were fatigue (32 %), rash (22 %), diarrhea (18 %) and pruritus (17 %).
  • 6The drug received Fast Track, Breakthrough Therapy, Priority Review and a National Priority Voucher, enabling accelerated approval ahead of the PDUFA date.

Sources